Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2000 Aug;2(3):139-44.
doi: 10.1016/S1525-1578(10)60629-0.

Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay

P M Duddy  1 , A M Hanby, D M Barnes, R S Camplejohn
Affiliations
Comparative Study

Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay

P M Duddy et al. J Mol Diagn. 2000 Aug.

Abstract

The aim of this investigation was to examine the ability of the yeast-based functional assay, the functional analysis for the separation of alleles in yeast (FASAY), to detect p53 mutations in breast cancers when compared with immunohistochemistry and automated sequencing of the whole p53 gene (exons 1-11). To achieve this, all three methods were carried out on a cohort of aggressive breast tumors. In those tumors, in which the FASAY analysis indicated the presence of a mutation, cDNA was extracted from red yeast colonies and was sequenced to identify the base change in the p53 gene. The FASAY detected all 24 mutations found in the series of 48 tumors, whereas initial automated sequencing of genomic DNA detected 18/24 mutations. A second round of automated sequencing carried out using an independent source of genomic DNA detected mutations in 3 of the 6 tumors that originally appeared to lack a mutation in genomic DNA. All but 1 of the mutations originally missed by sequencing of genomic DNA were point mutations. Five mutations in this series (21%) were outside the commonly investigated exons 5-8, reinforcing the need to extend sequencing beyond this region. Of 24 tumors, 14 had strong immunohistochemical staining, and all 14 had p53 mutations; the majority of mutations missed by immunohistochemistry produced a truncated protein. Strong staining was not seen in tumors lacking a p53 mutation. The FASAY proved to be a rapid, reliable, and effective method for identifying those breast tumors harboring p53 mutations.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Harris CC: p53 tumor suppressor gene from the basic research laboratory to the clinic: an abridged historical perspective. Carcinogenesis 1996, 17:1187-1198 - PubMed
    1. Barnes DM, Camplejohn RS: p53, apoptosis and breast cancer. J Mammary Gland Biol Neoplasia 1996, 1:163-175 - PubMed
    1. Aas T, Borresen AL, Geisler S, Smithsorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2:811-814 - PubMed
    1. Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, Wehage W, Jen J, Sidransky D: Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci USA 1999, 96:7382-7387 - PMC - PubMed
    1. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher J-M, Bron L, Benhattar J, Tada M, Van Meir EG, Estreicher A, Iggo RD: A simple p53 functional assay for screening cell lines, blood and tumors. Proc Natl Acad Sci USA 1995, 92:3963-3967 - PMC - PubMed

Publication types

MeSH terms

Substances